Health Condition 1: J848- Other specified interstitial pulmonary diseases
Conditions
Interventions
Intervention1: Nil: Nil
Intervention2: Nil: Nil
Intervention3: NIL: NIL
Control Intervention1: NIL: NIL
Sponsors
Amrita Institute of Medical Sciences and Research Centre
Eligibility
Inclusion criteria
Inclusion criteria: Patients aged eighteen years and above Patients with confirmed diagnosis of interstitial lung disease established through multidisciplinary discussion Diagnosis based on high resolution computed tomography chest findings consistent with interstitial lung disease and clinical evaluation with pulmonary function testing and histopathology where available Patients with any subtype of interstitial lung disease including idiopathic pulmonary fibrosis connective tissue disease associated interstitial lung disease hypersensitivity pneumonitis sarcoidosis with pulmonary involvement occupational or environmental interstitial lung disease drug induced interstitial lung disease and unclassifiable interstitial lung disease Patients willing and able to provide written informed consent
Exclusion criteria
Exclusion criteria: No confirmed ILD diagnosis on multidisciplinary discussion. Unable or unwilling to provide written informed consent.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Distribution of interstitial lung disease (ILD) subtypes among enrolled patients in the registry. Baseline clinical, radiological, and physiological characteristics of ILD patients across participating centres in India. Patterns of diagnosis and management of ILD in real-world clinical practice across centres.Timepoint: Baseline at enrolment; follow-up at 3 6 monthly intervals and as clinically indicated; annual outcome assessment; final assessment at 3 years or last contact. | — |
Secondary
| Measure | Time frame |
|---|---|
| Disease progression in ILD patients, assessed by change in pulmonary function (FVC, DLCO) over time. All-cause mortality and survival outcomes in patients with ILD during follow-up. Frequency of acute exacerbations, hospitalisations, and disease-related complications. Patterns of treatment usage, including antifibrotic agents, immunosuppressants, and combination therapies. Time from symptom onset to diagnosis and referral patterns across centres. Association of environmental and occupational exposures with ILD subtypes. Healthcare utilisation patterns, including outpatient visits, admissions, and need for advanced care (e.g., oxygen therapy, transplant referral).Timepoint: Baseline at enrolment; follow-up at 3 6 monthly intervals and as clinically indicated; annual outcome assessment; final assessment at 3 years or last contact. | — |
Countries
India
Contacts
Public ContactDr Asmita Mehta
Amrita institute of medical science
Outcome results
None listed